Browsing by Author "Rezvani, Aylin"
Now showing 1 - 7 of 7
- Results Per Page
- Sort Options
Publication Attitudes of patients with spondylarthritis or rheumatoid arthritis regarding biological treatment during covid-19 pandemic: A multi-center, phone-based, cross-sectional study(Türkiye Romatizma Araştırma ve Savaş Derneği, 2021-12-01) Zateri, Coskun; Birtane, Murat; Aktaş, İlknur; Sarıkaya, Selda; Rezvani, Aylin; Altan, Lale; Dursun, Nigar; Dursun, Erbil; Taştekin, Nurettin; Çeliker, Reyhan; Özdolap, Şenay; Akgün, Kenan; ALTAN İNCEOĞLU, LALE; 0000-0002-7948-5383; 0000-0002-1050-9666; 0000-0002-8015-0513; 0000-0002-6552-7204; AAH-1652-2021Objectives: In this study, we aimed to investigate the medical treatment attitudes of patients with spondylarthritis or rheumatoid arthritis (RA) who were using biological drugs during the novel coronavirus-2019 (COVID-19) pandemic.Patients and methods: In this multi-center, cross-sectional study, a total of 277 patients (178 males, 99 females; median age: 45 years; range, 20 to 77 years) who were using biological disease-modifying anti-rheumatic drugs (bDMARDs) for rheumatic diseases and were reached by phone between June 1st, 2020 and June 30th, 2020 were included. Demographic characteristics, working status, type of the rheumatic disease, comorbidities, smoking habits, and type of the bDMARDs were recorded. Disease activity was evaluated using the Visual Analog Scale (VAS). The patients were asked whether they continued the treatment plan, as it was before or changed and, if changed, how they changed the plan and what happened after the change.Results: Of the patients, 229 had spondylarthritis and 48 had RA. A total of 36.1% of the patients were smokers, and the most common comorbidity was hypertension (17.3%). Totally, 5.8% of the patients had a history of contact with a COVID-19 positive person. Only three (1.1%) patients were diagnosed with COVID-19 infection and none of them died. Of the patients, 64.3% continued their treatment, while 35.7% adopted various changes. Most patients made the decision about the treatment plan on their own (n=160, 57.8%), while 38.3% of them consulted their physicians and 13.9% of them consulted any health staff. The only significant parameter for changing the drug course was receiving intravenous bDMARDs (by infusion at hospital) (p=0.001). These patients had also a higher disease activity as measured by VAS, compared to the patients receiving non-infusion therapy (p=0.021). As a result of these changes, severity of the symptoms increased in 91 (32.9%) patients. Disruption of regular biological treatment and prior infusion therapy more likely worsened the complaints (p<0.001 and p=0.024, respectively).Conclusion: Intravenous bDMARD therapy seems to be the main factor affecting the continuity of the treatment in the pandemic period. During the pandemic period, alternative treatment options should be considered other than infusion therapy not to interrupt the treatment of these patients.Item Description of the registry of patients with ankylosing spondylitis in Turkey: TRASD-IP(Springer Heidelberg, 2012-01) Bodur, Hatice; Ataman, Şebnem; Buğdaycı, Derya Soy; Rezvani, Aylin; Nas, Kemal; Uzunca, Kaan; Emlakçıoğlu, Emel; Karatepe, Altınay Göksel; Durmuş, Bekir; Sezgin, Melek; Ayhan, Figen; Yazgan, Pelin; Duruöz, Tuncay; Yener, Mahmut; Gürğan, Alev; Kırnap, Mehmet; Çakar, Engin; Soydemir, Raikan; Çapkın, Erhan; Tekeoğlu, İbrahim; Aydın, Gülümser; Günendi, Zafer; Nacır, Barış; Şallı, Ali; Öztürk, Cihat; Memiş, Asuman; Turan, Yasemin; Kozanoğlu, Erkan; Sivrioğlu, Konçuy; Altan, Lale; Uludağ Üniversitesi/Tıp Fakültesi.; AAH-1652-2021; 6603281363A web-based application patient follow-up program was developed to create a registry of patients with ankylosing spondylitis (AS) by the Turkiye Romatizma Arastirma Savas Dernegi (TRASD) AS Study Group. This study describes the methodological background and patient characteristics. The patient follow-up program is a web-based questionnaire, which contains sections on socio-demographic data, anamnesis, personal and family history, systemic and musculoskeletal examination, laboratory and imaging data and treatment. Between October 1, 2007 and February 28, 2009, 1,381 patients from 41 centers were included in the registry (1,038 males [75.2%]; mean age 39.5 +/- A 10.7 years). Mean disease duration was 12.1 +/- A 8.5 years, and mean time from initial symptom to diagnosis was 5 +/- A 6.8 years (median 2 years). HLA-B27 positivity was detected in 73.7% of 262 patients tested. Manifestations of extraarticular involvement were anterior uveitis (13.2%), psoriasis and other skin and mucous membrane lesions (6%) and inflammatory bowel disease (3.8%). The prevalence of peripheral arthritis was 11.2%. In 51.7% of patients, the Bath AS Disease Activity Index was a parts per thousand yen4. But since our patients consisted of the ones with more severe disease who referred to the tertiary centers and needed a regular follow-up, they may not represent the general AS population. Disease-modifying anti-rheumatic drugs were being used by 41.9% of patients, with 16.4% using anti-TNF agents. TRASD-IP (Izlem Programi: Follow-up program) is the first AS registry in Turkey. Such databases are very useful and provide a basis for data collection from large numbers of subjects. TRASD-IP gives information on the clinical and demographic profiles of patients, and the efficacy and safety of anti-TNF drugs, examines the impact on quality of life, and provides real-life data that may be used in cost-effectiveness analyses.Item Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis(Türk Ortopedi ve Travmatoloji Derneği, 2015-10-05) Akarırmak, Ülkü; Kocyiğit, Hikmet; Eskiyurt, Nurten; Esmaeilzadeh, Sina; Kuru, Ömer; Yalcınkaya, Ebru Yılmaz; Peker, Özlen; Ekim, Ayşe Aydemir; Özgirgin, Neşe; Çalış, Mustafa; Rezvani, Aylin; Çevikol, Alev; Eyigör, Sibel; Şendur, Ömer Faruk; İrdesel, Jale Fatma; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; 56631533300Objective: In our study, we aimed to evaluate the influence of training on compliance and persistence with bisphosphonate treatment given on a weekly vs. monthly basis in postmenopausal osteoporosis patients. Methods: A total of 979 patients with postmenopausal osteoporosis (mean age: 63.2 +/- 7.2 years) were included in this national, multicenter, prospective non-interventional observational cohort registry study. Patients were randomized into training (n = 492, 50.3%, mean age: 63.4 +/- 7.2 years) and control (n = 487, 49.7%, mean age: 63.0 +/- 7.1 years) groups. Patients in each intervention group were given weekly (44.9% and 44.6% for training and control subjects, respectively) or monthly (55.1% and 55.4%, respectively) bisphosphonate regimens. After the initial visit, patients were followed up at three-month intervals throughout 12 months of treatment for evaluation of persistence, compliance and adverse events. Results: On average, 79.4% of the patients were persistent with the treatment with a mean of 350.4 days of duration during the 12-month follow-up period. The mean compliance in the compliant and fully compliant group remained at an average of 86.6%. No significant difference was detected between the training and control groups in terms of compliance and persistence. Significantly longer persistence (360.0 +/- 89.0 vs. 345.0 +/- 108.0 days; p = 0.035), higher percentage of persistent patients (83.4% vs. 74.2%; p = 0.012) and higher compliance rates (88.8% vs. 83.3%; p = 0.002) were noted in monthly regimen patients in comparison to those given weekly regimen. Conclusion: Our findings revealed remarkably high rates for persistence and compliance with bisphosphonate treatment in postmenopausal osteoporosis, with no impact of training on compliance and persistence rates. Longer persistence and better compliance rates were achieved with the monthly bisphosphonate regimen when compared to the weekly regimen.Item Quality of life and related variables in patients with ankylosing spondylitis(Springer, 2011-05) Bodur, Hatice; Ataman, Şebnem; Rezvani, Aylin; Buğdaycı, Derya Soy; Çevik, Remzi; Birtane, Murat; Akıncı, Ayşen; Altay, Zuhal; Günaydın, Rezzan; Yener, Mahmut; Koçyiğit, Hikmet; Duruöz, Tuncay; Yazgan, Pelin; Çakar, Engin; Aydın, Gülümser; Hepgüler, Simin; Kırnap, Mehmet; Ölmez, Neşe; Soydemir, Raikan; Kozanoğlu, Erkan; Bal, Ajda; Karkucak, Murat; Günendi, Zafer; Altan, Lale; Sivrioğlu, Koncuy; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; 56245687600; 6603281363To evaluate quality of life (QoL) and related variables in patients with ankylosing spondylitis (AS), a chronic inflammatory disease of the spine. Nine-hundred and sixty-two patients with AS from the Turkish League Against Rheumatism AS Registry, who fulfilled the modified New York criteria, were enrolled. The patients were evaluated using the Assessment of SpondyloArthritis International Society core outcome domains including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), fatigue (BASDAI-question 1), pain (last week/spine/due to AS), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), Bath Ankylosing Spondylitis Radiology Index (BASRI), Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and two QoL questionnaires (the disease-specific ASQoL and generic the Short Form-36 [SF-36]). The mean ASQoL score was 7.1 +/- A 5.7. SF-36 subscales of general health, physical role and bodily pain had the poorest scores. ASQoL was strongly correlated with disease duration, BASDAI, fatigue, BASFI, BASMI, BASRI, MASES, pain and SF-36 subscales (P < 0.001). SF-36 subscales were also strongly correlated with BASDAI and BASFI. Advanced educational status and regular exercise habits positively affected QoL, while smoking negatively affected QoL. In patients with AS, the most significant variables associated with QoL were BASDAI, BASFI, fatigue and pain. ASQoL was noted to be a short, rapid and simple patient-reported outcome (PRO) instrument and strongly correlated with SF-36 subscales.Item Reliability and validity of Turkish version of fibromyalgia participation questionnaire(Bmj Publishing, 2017-06) Çeliker, Reyhan; Birtane, Murat; Akgün, Kenan; Zateri, Coşkun; Taştekin, Nurettin; Rezvani, Aylin; Aktaş, İlknur; Özdolap, Şenay; Altan, Lale; Ercan, İlker; Uludağ Üniversitesi/Tıp Fakültesi/Fizik Tedavi ve Rehabilitasyon Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi.; AAH-1652-2021; ABF-2367-2020Item Reliability and validity of Turkish version of the fibromyalgia rapid screening tool (FIRST)(Bmj Publishing Group, 2016-06) Çeliker, Reyhan; Rezvani, Aylin; Aktaş, İlknur; Taştekin, Nurettin; Dursun, Erbil; Dursun, Nigar; Sarıkaya, Sevda; Özdolap, Şenay; Akgün, Kenan; Zateri, Coşkun; Birtane, Murat; Altan, Lale; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; AAH-1652-2021Item Turkish league against rheumatism national recommendations for the management of ankylosing spondylitis(Romatizmaya Karşı Türk Dili Yayınları, 2011) Bodur, Hatice; Sivas, Filiz; Yılmaz, Özlem; Özgöçmen, Salih; Günaydın, Rezzan; Kaya, Tacıser; Ataman, Şebnem; Altay, Zuhal; Aydoğ, Ece; Birtane, Murat; Borman, Pınar; Buğdaycı, Derya Soy; Bütün, Bülent; Çakırbay, Haşim; Duruöz, Tuncay; Gürer, Gülcan; Hepgüler, Simin; Kamanlı, Ayhan; Kuru, Ömer; Küçükdeveci, Ayşe; Nacir, Barış; Ölmez, Neşe; Rezvani, Aylin; Yanık, Burcu Çörekçi; Altan, Lale; Uludağ Üniversitesi/Tıp Fakültesi/Fiziksel Tıp ve Rehabilitasyon Anabilim Dalı.; AAH-1652-2021; 6603281363Objectives: To develop Turkish League Against Rheumatism (TLAR) National Recommendations for the management of ankylosing spondylitis (AS). Materials and methods: A scientific committee of 25 experts consisting of six rheumatologists and 19 physical medicine and rehabilitation specialists was formed by TLAR. Recommendations were based on the 2006 ASsessment in Ankylosing Spondylitis International Working Group(ASAS)/European League Against Rheumatism (EULAR) recommendations and a systematic review of associated publications between January 2005 and September 2010. A Delphi process was used to develop the recommendations. Twelve major recommendations were constructed for the management of AS. Voting using a numerical rating scale assessed the strength of each recommendation. Results: The 12 recommendations include patient assessment, patient follow-up along with pharmacological and non-pharmacological methods. Some minor additions and changes have been made to the ASAS/EULAR recommendations. All of the recommendations had sufficient strength. Conclusion: National recommendations for the management of AS were developed based on scientific evidence and consensus expert opinion. These recommendations will be updated regularly in accordance with recent developments.